STOCK TITAN
  1. Home
  2. News
  3. BNTC

Benitec Biopharma Inc - BNTC STOCK NEWS

Welcome to our dedicated news page for Benitec Biopharma (Ticker: BNTC), a resource for investors and traders seeking the latest updates and insights on Benitec Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Benitec Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Benitec Biopharma's position in the market.

News
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Rhea-AI Summary
Benitec Biopharma reports positive interim clinical trial data for the first OPMD subject treated with BB-301 in a Phase 1b/2a study. The gene therapy showed efficacy in improving swallowing function, a significant milestone for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). No serious adverse events were reported, with transient GERD resolved with common medications. The company is encouraged by the results and aims to continue treating patients in the study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.08%
Tags
clinical trial
-
News
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
Rhea-AI Summary
Benitec Biopharma Inc. announces an oversubscribed private placement financing of $40.0 million, with the sale of 5,749,152 shares of common stock and pre-funded warrants to certain institutional accredited investors. The financing was led by Suvretta Capital Management, , with participation from other investors. The company plans to use the proceeds for the clinical development and commercialization of BB-301, among other purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.08%
Tags
none
-
News
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
Rhea-AI Summary
Benitec Biopharma Inc. announces a virtual R&D Day to discuss gene therapy for oculopharyngeal muscular dystrophy. Key opinion leaders will review clinical symptoms, disease progression, and treatment landscape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
conferences
News
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
Rhea-AI Summary
Benitec Biopharma Inc. announces the dosing of the first subject with BB-301 in a Phase 1b/2a clinical treatment study for Oculopharyngeal Muscular Dystrophy. No dose-limiting toxicities observed, with positive recommendations for subject enrollment continuation. Financially, the company reported total revenues of $0, total expenses of $6.9 million, and a net loss of $6.8 million for the quarter ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
earnings
-
News
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
Rhea-AI Summary
Benitec Biopharma Inc. (NASDAQ: BNTC) has initiated the first clinical trial using its 'Silence and Replace' DNA-directed RNA interference gene therapy platform. The trial, called BB-301, is for the treatment of Oculopharyngeal Muscular Dystrophy-related Dysphagia, a chronic, life-threatening genetic disorder affecting approximately 15,000 patients in the United States, Canada, Western Europe, and Israel. The first subject has been dosed, marking the beginning of a 52-week follow-up period to evaluate primary and secondary endpoints. Interim safety and efficacy evaluations will be conducted every 90 days. The company aims to improve the lives of patients suffering from OPMD through its gene therapy approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
clinical trial
-
News
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Summary
Benitec Biopharma Inc. (NASDAQ: BNTC) announced that Jerel A. Banks, M.D., Ph.D., will participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference. The live webcast will be accessible from the Investor section of Benitec’s website at ir.benitec.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
conferences
News
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
Rhea-AI Summary
Benitec Biopharma Inc. (NASDAQ: BNTC) announced financial results for Q1 2024, including the enrollment of 19 subjects in the OPMD Natural History Study and the upcoming BB-301 Phase 1b/2a Clinical Treatment Study. The company also provided operational and regulatory updates, as well as financial highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
earnings
-
News
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
Rhea-AI Summary
Benitec Biopharma receives FDA clearance for BB-301 IND application for the treatment of OPMD-related dysphagia. Successful closing of a $30.9M public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
earnings
-
News
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering
Rhea-AI Summary
Benitec Biopharma Inc. has closed its underwritten public offering, raising approximately $30.9 million. The company sold 15,544,041 shares of common stock and accompanying warrants at a combined offering price of $1.93. The proceeds will be used to support the clinical development of BB-301 and other product candidates, as well as for general corporate purposes and strategic growth opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
offering
News
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
Rhea-AI Summary
Benitec Biopharma Inc. announces pricing of public offering, expected to raise approximately $30 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
65.8%
Tags
offering
Stock BNTC logo
Benitec Biopharma Inc

Nasdaq:BNTC

BNTC Rankings

#5187 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BNTC Stock Data

12.39M
2.02M
6.81%
55.14%
0.42%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Australia
Melbourne

About BNTC

benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.